AVAX Technologies, Inc. (AVXT)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2007 | -6.11 Million USD | -22.73% |
| 2006 | -5.06 Million USD | -47.54% |
| 2005 | -3.38 Million USD | -24.62% |
| 2004 | -2.83 Million USD | -0.54% |
| 2003 | -2.82 Million USD | 68.15% |
| 2002 | -8.84 Million USD | 25.73% |
| 2001 | -11.91 Million USD | -74.65% |
| 2000 | -12.02 Million USD | -11.82% |
| 1999 | -8.2 Million USD | 10.29% |
| 1998 | -6.19 Million USD | -17.24% |
| 1997 | -4.7 Million USD | -132.0% |
| 1996 | -1.7 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2008 Q2 | -1.83 Million USD | 3.06% |
| 2008 Q1 | -1.89 Million USD | -11.64% |
| 2008 Q3 | -1.8 Million USD | 1.98% |
| 2007 FY | - USD | -22.73% |
| 2007 Q1 | -1.26 Million USD | 6.28% |
| 2007 Q2 | -1.53 Million USD | -21.32% |
| 2007 Q3 | -1.89 Million USD | -23.88% |
| 2007 Q4 | -1.69 Million USD | 10.57% |
| 2006 Q1 | -1.28 Million USD | 2.5% |
| 2006 Q3 | -1.32 Million USD | -6.95% |
| 2006 FY | - USD | -47.54% |
| 2006 Q4 | -1.34 Million USD | -1.42% |
| 2006 Q2 | -1.24 Million USD | 3.57% |
| 2005 Q3 | -612.74 Thousand USD | 46.74% |
| 2005 Q2 | -1.15 Million USD | -158.37% |
| 2005 FY | - USD | -24.62% |
| 2005 Q1 | -445.26 Thousand USD | 35.66% |
| 2005 Q4 | -1.32 Million USD | -115.69% |
| 2004 Q1 | -820.71 Thousand USD | 37.16% |
| 2004 Q4 | -691.99 Thousand USD | 9.35% |
| 2004 Q3 | -763.33 Thousand USD | -37.13% |
| 2004 Q2 | -556.63 Thousand USD | 32.18% |
| 2004 FY | - USD | -0.54% |
| 2003 Q1 | -989.18 Thousand USD | 26.19% |
| 2003 FY | - USD | 68.15% |
| 2003 Q3 | -670.96 Thousand USD | -535.34% |
| 2003 Q4 | -1.31 Million USD | -94.64% |
| 2003 Q2 | 154.12 Thousand USD | 115.49% |
| 2002 Q4 | -1.34 Million USD | 46.9% |
| 2002 FY | - USD | 25.73% |
| 2002 Q1 | -2.5 Million USD | -16.57% |
| 2002 Q3 | -1.92 Million USD | -3.33% |
| 2002 Q2 | -2.25 Million USD | 1.94% |
| 2001 Q4 | -2.14 Million USD | 34.19% |
| 2001 Q3 | -3.03 Million USD | -27.05% |
| 2001 Q2 | -2.57 Million USD | 30.84% |
| 2001 FY | - USD | -74.65% |
| 2001 Q1 | -3.49 Million USD | -1191.03% |
| 2000 Q3 | -3.92 Million USD | 33.62% |
| 2000 Q4 | 340.59 Thousand USD | 117.92% |
| 2000 FY | - USD | -11.82% |
| 2000 Q2 | -2.86 Million USD | -19.4% |
| 2000 Q1 | -2.39 Million USD | -118.01% |
| 1999 Q2 | -2.09 Million USD | -17.65% |
| 1999 Q3 | -2.09 Million USD | 0.0% |
| 1999 Q1 | -1.69 Million USD | -6.25% |
| 1999 Q4 | -1.1 Million USD | 45.0% |
| 1999 FY | - USD | 10.29% |
| 1998 Q1 | -1.5 Million USD | -6.25% |
| 1998 FY | - USD | -17.24% |
| 1998 Q4 | -1.5 Million USD | 0.0% |
| 1998 Q3 | -1.4 Million USD | 15.79% |
| 1998 Q2 | -1.9 Million USD | -11.76% |
| 1997 Q2 | -1.6 Million USD | -23.08% |
| 1997 Q3 | -900 Thousand USD | 25.0% |
| 1997 FY | - USD | -132.0% |
| 1997 Q4 | -1.3 Million USD | -33.33% |
| 1997 Q1 | -1 Million USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 91.395% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -3.099% |
| SQZ Biotechnologies Company | -64.14 Million USD | 90.47% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 64.809% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 106.5% |
| Mesoblast Limited | -62.38 Million USD | 90.202% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -297.946% |
| Genus plc | 73.7 Million USD | 108.294% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 7.546% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -72.333% |
| Marizyme, Inc. | -34.28 Million USD | 82.169% |
| ContraFect Corporation | -64.99 Million USD | 90.596% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 30.316% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -35.05% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -336.054% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -131.15% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -163.043% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -1079.942% |
| Accustem Sciences Inc. | -3.74 Million USD | -63.16% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 87.325% |
| EV Biologics, Inc. | -1.26 Million USD | -382.4% |
| Q BioMed Inc. | -617.62 Thousand USD | -889.697% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 271.127% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -866.569% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -167.572% |
| Biomind Labs Inc. | -1.03 Million USD | -490.851% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 161.888% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 14.643% |
| Skye Bioscience, Inc. | -13.54 Million USD | 54.88% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -310.958% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -24350.572% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -57.367% |
| IMV Inc. | -35.52 Million USD | 82.793% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 61.482% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -144.314% |
| GB Sciences, Inc. | -1.41 Million USD | -330.503% |
| Alpha Cognition Inc. | -9.7 Million USD | 37.019% |
| HST Global, Inc. | -5303.00 USD | -115167.641% |
| CSL Limited | 4.78 Billion USD | 100.128% |
| Halberd Corporation | -74.27 Thousand USD | -8129.302% |
| Enzolytics Inc. | -2.12 Million USD | -188.057% |
| Resverlogix Corp. | -11.74 Million USD | 47.942% |
| Affymax, Inc. | -14.29 Million USD | 57.239% |
| SYBLEU INC | -141.57 Thousand USD | -4217.723% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -99.563% |
| argenx SE | -216.02 Million USD | 97.17% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 88.954% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 602.271% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -307.807% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 1713.499% |
| Zenith Capital Corp. | -8.6 Million USD | 28.972% |
| Genscript Biotech Corporation | -248.71 Million USD | 97.542% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -34987.785% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -149.857% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -3372.612% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 84.578% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -111.34% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -484.208% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 91007.838% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -249.294% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -218.216% |
| BioStem Technologies, Inc. | -7.55 Million USD | 19.077% |
| ONE Bio Corp. | 13.61 Million USD | 144.903% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -3275.51% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -197.163% |
| Agentix Corp. | -1.37 Million USD | -345.607% |
| LadRx Corporation | 412.28 Thousand USD | 1582.633% |
| Cell Source, Inc. | -4.27 Million USD | -43.069% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -1564.568% |
| Regen BioPharma, Inc. | 1.46 Million USD | 516.973% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -552.399% |
| NovAccess Global Inc. | -1.03 Million USD | -490.709% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 169.04% |
| Itoco Inc. | -1.86 Million USD | -227.055% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -1510.2% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -447.728% |
| Kadimastem Ltd | -2.62 Million USD | -132.918% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -2455.987% |
| CytoDyn Inc. | -18.02 Million USD | 66.095% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -7634.683% |
| Mobile Lads Corp. | -2.24 Million USD | -172.745% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -49884.815% |
| Qrons Inc. | -40.08 Thousand USD | -15150.725% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -1158.579% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 1258.942% |
| Rebus Holdings, Inc. | -951 Thousand USD | -542.76% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -475.573% |
| International Stem Cell Corporation | 202 Thousand USD | 3126.061% |
| Bioxytran, Inc. | -3.82 Million USD | -60.011% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -11512.164% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -148.286% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 82.958% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -13483.651% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -123.252% |
| Neutra Corp. | -181.24 Thousand USD | -3272.549% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 69.678% |
| PureTech Health plc | -11.62 Million USD | 47.427% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 69.676% |
| IXICO plc | -707 Thousand USD | -764.589% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 20.46% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 87.356% |
| CSL Limited | 4.73 Billion USD | 100.129% |
| Cellectis S.A. | -92.63 Million USD | 93.401% |